Universal Beteiligungs und Servicegesellschaft mbH Sells 21,558 Shares of Boston Scientific Corporation $BSX

Universal Beteiligungs und Servicegesellschaft mbH lessened its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.6% in the third quarter, HoldingsChannel reports. The fund owned 1,333,127 shares of the medical equipment provider’s stock after selling 21,558 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Boston Scientific were worth $130,153,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC increased its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. Farther Finance Advisors LLC raised its position in shares of Boston Scientific by 8.4% during the second quarter. Farther Finance Advisors LLC now owns 13,079 shares of the medical equipment provider’s stock worth $1,405,000 after acquiring an additional 1,017 shares during the last quarter. Park Avenue Securities LLC boosted its stake in shares of Boston Scientific by 7.6% in the 2nd quarter. Park Avenue Securities LLC now owns 49,581 shares of the medical equipment provider’s stock valued at $5,325,000 after purchasing an additional 3,499 shares during the last quarter. U.S. Capital Wealth Advisors LLC raised its position in shares of Boston Scientific by 7.8% in the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 4,529 shares of the medical equipment provider’s stock worth $486,000 after acquiring an additional 326 shares in the last quarter. Finally, CRA Financial Services LLC boosted its holdings in shares of Boston Scientific by 8.0% during the 2nd quarter. CRA Financial Services LLC now owns 3,769 shares of the medical equipment provider’s stock worth $405,000 after buying an additional 278 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 3.5%

Shares of NYSE:BSX opened at $91.16 on Wednesday. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. The stock’s 50-day moving average price is $96.42 and its 200-day moving average price is $100.06. The stock has a market capitalization of $135.14 billion, a P/E ratio of 48.75, a price-to-earnings-growth ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the company posted $0.63 EPS. Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on BSX shares. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. BTIG Research restated a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research note on Friday, November 21st. Robert W. Baird lifted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Needham & Company LLC reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Thursday, January 15th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Boston Scientific in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $123.89.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.